Sanofi's Flu Vaccine Antitrust Commitments

Sanofi's flu-vaccine climbdown hands Brussels its antitrust playbook

Sanofi has offered binding EU commitments to stop disparaging CSL's Fluad flu shot — a case that now sets the template for Article 102 policing of pharma marketing.

Sanofi's decision on July 8, 2026 to accept binding EU commitments not to badmouth CSL Seqirus's rival Fluad vaccine — barely 12 days after Brussels opened a formal probe — is not really about flu shots. It is about a French national champion moving fast to avoid becoming the next Teva, and about the European Commission consolidating a decade-old French legal theory into a bloc-wide enforcement standard: under Article 102 of the Treaty on the Functioning of the European Union, telling doctors your competitor's medicine is worse than it is can be an abuse of dominance in itself. That standard, once niche, is now the Commission's fastest-moving pharma tool.

What Sanofi actually conceded

The commitments, published for market test by DG Competition, oblige Sanofi to post a two-year notice on its French and German websites stating that the national immunisation technical advisory groups in both countries "have assessed both vaccines and recommend them equally for elderly people," according to a Reuters wire carried by WNFL. Sanofi will also stop portraying Fluad as less safe or effective than its own high-dose Efluelda and stop mischaracterising the underlying scientific studies. The offer runs until March 2030. Third parties have until August 21, 2026 to file objections before the Commission decides whether to make the package legally binding under Article 9 of Regulation 1/2003, per the Commission's pharmaceutical competition news page.

The trigger was DG Competition's June 26, 2026 opening decision. The Commission found preliminarily that Sanofi "may be dominant in the market for enhanced flu vaccines in Germany and France" and that its promotional campaign for Efluelda may have disparaged the "only rival flu vaccine recommended for vulnerable patients with risk factors" — CSL Seqirus's MF59-adjuvanted Fluad — thereby restricting competition, according to the Commission's own case announcement. Sanofi disputes the allegation but told regulators it wants "a swift conclusion."

The pattern is now familiar. When the Commission opened a Statement of Objections in April 2024 against Vifor — a CSL subsidiary, incidentally — for disparaging Pharmacosmos's Monofer iron therapy, Vifor caved within three months, offering a 10-year no-badmouthing regime that DG Competition made binding on July 22, 2024. That decision, IP/24/3907, and its accompanying Official Journal notice are the direct architectural precedent for Sanofi's offer: mandatory clarificatory communication to healthcare professionals, prohibited-conduct clauses tied to the product's Summary of Product Characteristics and head-to-head trials only, and a monitoring trustee. Expect the final Sanofi text to look near-identical.

The power dynamic: it is the fine, not the flu shot

Sanofi's speed is best understood through one number. Under Article 23(2) of Regulation 1/2003, the Commission can fine a company up to 10% of global annual turnover for an Article 102 infringement. On the €41.3 billion Sanofi booked in 2024, and the €10.5 billion of Q1 2026 sales it reported to the Financial Times markets service, the theoretical ceiling clears €4 billion. Efluelda is a growth product, not a franchise on that scale. Faced with even a fractional application of that ceiling — Teva was hit with €462.6 million in October 2024 for disparaging a multiple sclerosis rival, per the same Commission news feed — the rational move is to concede the marketing conduct and preserve the product.

The revenue asymmetry is the real story. CSL Seqirus's Fluad is the only enhanced flu vaccine indicated from age 50 in the EU and the standing comparator to Efluelda for over-65s, per the UK Health Security Agency's 2026–27 marketed vaccine list. Head-to-head real-world evidence is thin and inconvenient for both sides: Danish surveillance data published in Eurosurveillance found the adjuvanted quadrivalent vaccine (Fluad's category) delivered 48% effectiveness against 33% for standard-dose in 2024/25, and "the high-dose QIV demonstrated similar effectiveness to the adjuvanted QIV," per the peer-reviewed abstract. A larger npj Vaccines analysis of 811,728 Israeli vaccinees found the incremental benefit of high-dose over standard-dose was statistically indistinguishable across two seasons, with a number-needed-to-vaccinate to prevent one hospitalisation of 2,262 to 7,662, according to the published paper. In that evidentiary landscape, marketing claims of superiority are legally exposed — because they are scientifically contested.

Why the Commission chose commitments over a fine

DG Competition's choice to accept commitments rather than push for an infringement decision is deliberate. The Commission's own 2025 ex-post evaluation of antitrust remedies found that Article 9 commitments — market-tested, monitored by trustees — are being used more flexibly and, crucially, deliver faster corrective effects on live markets than lengthy Article 7 prohibition proceedings that end up in the Court of Justice. For a vaccine sold seasonally, speed matters: a clarificatory notice on Sanofi.fr in autumn 2026 changes prescribing behaviour before the 2026–27 flu season peaks; a €400 million fine in 2029 does not.

There is precedent for that reasoning inside Sanofi's own file. In May 2013, the French Autorité de la concurrence fined Sanofi-Aventis €40.6 million for a "comprehensive communication strategy aimed at misleading physicians and pharmacists" about generic Plavix, a decision upheld by the Paris Court of Appeal and the Cour de cassation, according to the Commission's 2018 pharma sector report. The Plavix case is the intellectual seed of the current European doctrine that misleading medical communications by dominant firms are Article 102 abuses. Sanofi is being litigated against with a theory it helped invent.

Who wins, who loses

CSL Seqirus is the immediate beneficiary but not the largest. The corrective notice will run on Sanofi's German and French websites, the two largest enhanced-vaccine markets in the EU, where the Eurostat preventive-services release records that 47.1% of EU citizens over 65 were vaccinated against influenza in 2023 — with wide variation across member states. In France and Germany specifically, the two enhanced products compete head-to-head under STIKO and HAS recommendations that treat both as acceptable options. Removing Sanofi's comparative claims narrows Efluelda's edge in tenders and hospital formularies.

The larger structural winner is DG Competition. Between the Vifor decision in 2024, the Teva fine three months later, the Zoetis dog-medicine probe opened in March 2024, and now Sanofi, the Commission has strung together a coherent enforcement line: dominant pharma companies cannot use their medical-affairs teams as marketing arms. Each case ratchets the deterrent effect. The template published in the Vifor Official Journal notice — required communication + prohibited conduct + monitoring trustee — is now the standard remedy. Expect it in oncology and biologics within two years.

The loser Sanofi will worry most about is not CSL but its own future regulators. Belén Garijo took over as chief executive of Sanofi in mid-2026, per the company's Q1 2026 disclosure. Accepting commitments avoids a formal infringement finding, which matters for a company also submitting bids under the €225 million influenza pre-commercial procurement the Commission announced on February 20, 2026 through its Health Emergency Preparedness and Response Authority (HERA) — a contract Sanofi Pasteur is party to. An open Article 102 infringement would complicate that.

What to watch next

• August 21, 2026 — Deadline for third-party comments on Sanofi's commitments. CSL Seqirus, hospital purchasing groups (UniHA in France, GPO consortia in Germany) and payer associations will file. Watch for demands to widen the geographic scope beyond France and Germany, and to lengthen the notice from two years to the 10-year Vifor standard.
• Q4 2026 — Commission decision on whether to accept the commitments as final. If accepted, the corrective notice must be live before the 2026–27 flu season procurement cycles close.
• March 2030 — Sunset of the current commitment period. By then, expect DG COMP to have opened at least two further disparagement cases in oncology or biosimilars, using the identical template.
• Belén Garijo's first commercial policy signal — The new CEO's handling of the Efluelda medical-affairs playbook in the US market, where similar high-dose vs adjuvanted competition exists with CSL and where Sanofi flagged US flu-season shipments in a March 14, 2025 release, will show whether the European climbdown is a compliance reset or a jurisdiction-limited concession.

Diplomat View

Sanofi's commitments are being framed by wires as a corporate hiccup. They are not. They are the moment the European Commission's disparagement doctrine — built out of a 2013 French case, tested on Vifor in 2024, industrialised through Teva later that year — became the operative constraint on how dominant pharma companies talk to European doctors. Our forecast: the Commission accepts the commitments in Q4 2026 with minor extensions of geographic scope, and by end-2027 opens a comparable case against a biologics originator using near-identical remedy language. What would falsify that call: a Court of Justice ruling narrowing the "disparagement as abuse" theory (no such case is pending), or a new College of Commissioners deprioritising pharma enforcement after the 2029 term change. Neither is currently visible. The immediate corporate lesson — for GSK, Pfizer, Moderna and CSL itself — is that comparative medical-affairs slides now need antitrust sign-off, not just legal-medical review. The audience in Brussels is watching. See also our coverage of Global Politics.

The Bottom Line

Sanofi's July 8 commitments are not a settlement of a flu-shot dispute — they are the ratification of a Commission enforcement template that treats dominant-firm marketing claims as an Article 102 abuse in their own right. The winner is not CSL Seqirus, whose Fluad gets a two-year corrective notice in two countries; the winner is DG Competition, which now has a fourth clean pharma case in 24 months and a remedy playbook it can port directly to oncology and biologics. Every European medical-affairs department should be reading the Vifor Official Journal notice this week.